Literature DB >> 32060148

Epstein-Barr Virus miRNA BART2-5p Promotes Metastasis of Nasopharyngeal Carcinoma by Suppressing RND3.

Chen Jiang1,2,3, Lei Li1,3, Yan-Qun Xiang4, Maria Li Lung3, Tingting Zeng1, Jiabin Lu2, Sai Wah Tsao5, Mu-Sheng Zeng1, Jing-Ping Yun2, Dora L W Kwong3, Xin-Yuan Guan6,3.   

Abstract

Nasopharyngeal carcinoma is an Epstein-Barr virus (EBV)-related malignancy. Recently, we found that the EBV-encoded miRNA BART2-5p was increased in the serum of patients with preclinical nasopharyngeal carcinoma and that the copy number positively correlated with disease progression. In this study, we established its role in nasopharyngeal carcinoma progression and explored underlying mechanisms and clinical significance. BART2-5p was an independent unfavorable prognostic factor for progression-free survival and its circulating abundance positively associated with distant metastasis. Ectopic expression of BART2-5p promoted migration and invasion of EBV-negative nasopharyngeal carcinoma cells, whereas genetic downregulation of BART2-5p in EBV-positive nasopharyngeal carcinoma cells decreased aggressiveness. Mechanistically, BART2-5p targeted RND3, a negative regulator of Rho signaling. Downregulation of RND3 phenocopied the effect of BART2-5p and reconstitution of RND3 rescued the phenotype. By suppressing RND3, BART2-5p activated Rho signaling to enhance cell motility. These findings suggest a novel role for EBV miRNA BART2-5p in promoting nasopharyngeal carcinoma metastasis and its potential value as a prognostic indicator or therapeutic target. SIGNIFICANCE: This study shows that EBV-encoded BART2-5p miRNA suppresses expression of the RND3 Rho family GTPase, consequently promoting ROCK signaling, cell motility, and metastatic behavior of NPC cells. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 32060148     DOI: 10.1158/0008-5472.CAN-19-0334

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Identification and characterization of a new isoform of small GTPase RhoE.

Authors:  Yuan Dai; Weijia Luo; Xiaojing Yue; Wencai Ma; Jing Wang; Jiang Chang
Journal:  Commun Biol       Date:  2020-10-15

2.  Identification of potential plasma biomarkers in early-stage nasopharyngeal carcinoma-derived exosomes based on RNA sequencing.

Authors:  Wei Zheng; Wangzhong Ye; Zijie Wu; Xinyi Huang; Yuanji Xu; Qinyan Chen; Zhizhong Lin; Yanyu Chen; Penggang Bai; Chuanben Chen
Journal:  Cancer Cell Int       Date:  2021-03-31       Impact factor: 5.722

3.  MicroRNA-483-5p Predicts Poor Prognosis and Promotes Cancer Metastasis by Targeting EGR3 in Nasopharyngeal Carcinoma.

Authors:  Xi-Zhao Li; Yi-Jun Tu; Ting Zhou; Jiang-Bo Zhang; Ruo-Wen Xiao; Da-Wei Yang; Pei-Fen Zhang; Peng-Tao You; Xiao-Hui Zheng
Journal:  Front Oncol       Date:  2021-10-15       Impact factor: 6.244

4.  Identification of a 3-miRNA Signature Associated With the Prediction of Prognosis in Nasopharyngeal Carcinoma.

Authors:  Jinhui Zhou; Bo Zhang; Xin Zhang; Chengyu Wang; Yu Xu
Journal:  Front Oncol       Date:  2022-01-27       Impact factor: 6.244

5.  Prognostic Epstein-Barr Virus (EBV) miRNA biomarkers for survival outcome in EBV-associated epithelial malignancies: Systematic review and meta-analysis.

Authors:  Mai Abdel Haleem Abusalah; Ahmad Adebayo Irekeola; Rafidah Hanim Shueb; Mu'taman Jarrar; Chan Yean Yean
Journal:  PLoS One       Date:  2022-04-18       Impact factor: 3.752

6.  Epstein-Barr virus-encoded microRNA BART22 serves as novel biomarkers and drives malignant transformation of nasopharyngeal carcinoma.

Authors:  Ting Zhang; Zui Chen; Jing Deng; Kaixiong Xu; Di Che; Jiamin Lin; Ping Jiang; Xiaoqiong Gu; Banglao Xu
Journal:  Cell Death Dis       Date:  2022-07-30       Impact factor: 9.685

7.  EBV-encoded miRNAs can sensitize nasopharyngeal carcinoma to chemotherapeutic drugs by targeting BRCA1.

Authors:  Raymond Wai-Ming Lung; Joanna Hung-Man Tong; Lok-Man Ip; Ka-Hei Lam; Anthony Wing-Hung Chan; Wing-Po Chak; Lau-Ying Chung; Walter Wai Yeung; Pok-Man Hau; Shuk-Ling Chau; Sai-Wah Tsao; Kin-Mang Lau; Kwok-Wai Lo; Ka-Fai To
Journal:  J Cell Mol Med       Date:  2020-10-19       Impact factor: 5.295

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.